ClinicalTrials.gg
TerminatedNCT04863248PRESERVE 4Updated Apr 14, 2023Results posted

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

A Phase 2 interventional study of Trilaciclib and Placebo in Metastatic Non-Small Cell Lung Cancer, NSCLC and Lung Cancer, sponsored by G1 Therapeutics, Inc.. Terminated at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-14.

Sponsored by G1 Therapeutics, Inc. (part of Pharmacosmos A/S) · Phase 2, Interventional, and Treatment

Why this study was terminated
Treatment paradigm in second- and third-line NSCLC is shifting away from docetaxel, the backbone chemotherapy therapy used in this study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
2,583rd of 2,995
10 · median 56
Started
2021
with 181 others
Phase 2
1,078 of 3,368
119 open now
Registered
2,501st of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 2,583rd largest by enrollment of the 2,995 interventional ones that give a count, is one of 182 that started in 2021, is one of 1,078 in phase 2, and was the 2,501st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with metastatic NSCLC treated in the 2nd or 3rd line setting.

Read the detailed description

Patients must have documented disease progression during or after one or two lines of systemic therapy for recurrent or metastatic NSCLC. Prior treatment must have included, either in the same line or as separate lines of therapy: 1) a maximum of 1 line of platinum-containing chemotherapy for recurrent/metastatic disease and 2) a maximum of 1 line of a locally approved/authorized programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) containing regimen for recurrent/metastatic disease.

Patients will be randomly assigned (1:1) to receive trilaciclib or placebo intravenously (IV) prior to docetaxel on Day 1 of each 21-day cycle.

The study will include a screening phase, a treatment phase and a survival follow-up phase. The patient may continue to receive treatment on study until disease progression, unacceptable toxicity, withdrawal of consent, discontinuation by Investigator, or the end of the trial, whichever occurs first.

This study was terminated by the Sponsor for non-safety reasons. At the time of study termination, 10 patients had been screened, 7 were randomized, and 2 of the 7 had discontinued from the study. In addition, it was decided that there would be no statistical analyses of the efficacy or safety data due to the limited number of patients treated (N=7).

03

Conditions studied

  • Metastatic Non-Small Cell Lung Cancer
  • NSCLC
  • Lung Cancer

Keywords

  • Trilaciclib
  • Lung Cancer
  • Non-Small Cell Lung Cancer
  • PRESERVE 4
  • CDK 4/6 Inhibitor
  • cyclin-dependent kinase 4/6 inhibitor
  • Preserve
  • NSCLC
  • solid tumors
  • chemotherapy
  • metastatic
  • myeloprotection
  • advanced
  • stage 4
  • lung
  • docetaxel
  • COSELA
  • G1T28
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years of age at the time of signing the .
  • or cytologically confirmed NSCLC (squamous or nonsquamous) with no known actionable driver mutations (eg, EGFR, ROS1, ALK).

    1. Patients must have had documented disease progression during or after 1 or 2 for recurrent or metastatic disease.
    2. Two components of treatment must have been received in the same line or as separate lines of therapy: (i) a maximum of 1 line of platinum-containing chemotherapy regimen for recurrent/metastatic disease, and (ii) a maximum of 1 line of a locally approved/authorized /PD-L1 mAb containing regimen for recurrent/metastatic disease.
    3. Maintenance therapy following platinum doublet-based chemotherapy is not considered as a separate line of therapy. Maintenance therapy is defined as therapy given within 42 days after the last dose of platinum-based chemotherapy in patients with ongoing clinical benefit (complete response [CR], partial response [PR] or stable disease [SD]).
  • Measurable or non- per v1.1.
  • (ECOG) Performance Status of 0 to 2.
  • A formalin-fixed paraffin-embedded (FFPE) tumor specimen (from archival or fresh ) with an associated pathology report documenting NSCLC must be available to send to the Sponsor, within the specified timeframe, for planned retrospective biomarker analyses.
  • Adequate organ function defined by the normal laboratory values.

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with docetaxel.
  • Any to the administration of docetaxel at the discretion of the investigator.
  • Mixed NSCLC/SCLC, or lung tumors whose predominant histology is sarcomatoid, or neuroendocrine.
  • Any chemotherapy, immunotherapy, biologic, , or hormonal therapy for cancer treatment (except for hormonal therapy for breast cancer or prostate cancer defined as M0 disease or prostate-specific antigen (PSA) persistence/recurrence without disease) within 3 weeks prior to the first dose of trilaciclib/placebo.
  • Any radiotherapy within 2 weeks prior to the first dose of trilaciclib/placebo.
  • Presence of central nervous system (CNS) metastases requiring immediate treatment with radiation therapy or (i.e., patient must be off steroids administered for for at least 14 days prior to the first dose of trilaciclib/placebo).
  • Presence of .
  • Significant third-space fluid retention (eg, ascites or pleural effusion) not amenable to required repeat drainage.
  • corrected using Fridericia's formula (QTcF) interval >480 msec at screening (confirmed on repeat). For patients with ventricular pacemakers, QTcF >500 msec.
  • Symptomatic peripheral neuropathy.
  • History of interstitial lung disease (ILD).
  • Prior allogeneic or autologous hematopoietic stem cell or bone marrow transplantation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    trilaciclib + docetaxel

    Patients will receive trilaciclib administered IV prior to docetaxel administered IV on Day 1 of each 21-day cycle.

    Drug: Trilaciclib · Drug: Docetaxel

  • Placebo comparator
    placebo + docetaxel

    Patients will receive placebo administered IV prior to docetaxel administered IV on Day 1 of each 21-day cycle.

    Drug: Placebo · Drug: Docetaxel

Interventions

  • Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.

    Also known as: COSELA, G1T28

  • DrugPlacebo

    Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.

    Also known as: 0.9% sodium chloride, 5% Dextrose in water (D5W)

  • Docetaxel administered IV on Day 1 of each 21-day cycle.

    Also known as: Taxotere, Docefrez

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0

    To assess the effects of trilaciclib administered prior to docetaxel compared with placebo administered prior to docetaxel on occurrence and severity of adverse events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5, study treatment discontinuation due to adverse events (AEs), and trilaciclib adverse events of special interest (AESI) in patients with metastatic NSCLC receiving docetaxel in the second or third line.

    Time frame: Time from date of first dose of trilaciclib/placebo and docetaxel through 30 days following the last dose of trilaciclib/placebo and docetaxel, assessed up to 9 months and 2 days.

07

Results

Posted Apr 14, 2023
Limitations and caveats
This study was terminated earlier than initially proposed by the Sponsor for non-safety related reasons; only 7 patients were randomized and treated. Therefore, only limited safety summary tables were generated, and no efficacy analyses were conducted.

Participant flow

Due to the rapidly evolving treatment landscape for patients with metastatic NSCLC, G1 Therapeutics announced the decision to terminate this study on 03 November 2021. This study was not terminated for reasons related to safety. At the time of study termination, 10 patients had been screened, 7 were randomized, and 2 of the 7 had already discontinued from the study.

Participant flow — Overall Study
MilestoneTrilaciclib + DocetaxelPlacebo + Docetaxel
Started43
Completed00
Not completed43
Withdrew: Sponsor terminated41
Withdrew: Death01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryIncidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0

To assess the effects of trilaciclib administered prior to docetaxel compared with placebo administered prior to docetaxel on occurrence and severity of adverse events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5, study treatment discontinuation due to adverse events (AEs), and trilaciclib adverse events of special interest (AESI) in patients with metastatic NSCLC receiving docetaxel in the second or third line.

Time frame:
Time from date of first dose of trilaciclib/placebo and docetaxel through 30 days following the last dose of trilaciclib/placebo and docetaxel, assessed up to 9 months and 2 days.
Reported as:
Number · participants
Incidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0
participantsTrilaciclib + DocetaxelPlacebo + Docetaxel
Any AE43
Any AE of Grade >= 323
Any AE of Grade >= 403

Adverse events

Collected over 9 months, 2 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trilaciclib + Docetaxel0/4 (0%)1/4 (25%)4/4 (100%)
Placebo + Docetaxel1/3 (33.3%)3/3 (100%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventTrilaciclib + DocetaxelPlacebo + Docetaxel
Staphylococcal sepsisInfections and infestations0/41/3
Acute kidney injuryRenal and urinary disorders0/41/3
UrosepsisInfections and infestations0/41/3
Renal failureRenal and urinary disorders0/41/3
PneumoniaInfections and infestations1/40/3
Most frequent other events
Showing 10 of 48
Most frequent other events
EventTrilaciclib + DocetaxelPlacebo + Docetaxel
LeukopeniaBlood and lymphatic system disorders1/43/3
NeutropeniaBlood and lymphatic system disorders2/43/3
MonocytopeniaBlood and lymphatic system disorders3/41/3
LymphopeniaBlood and lymphatic system disorders0/42/3
EosinopeniaBlood and lymphatic system disorders1/42/3
Metamyelocyte count increasedInvestigations0/42/3
MonocytosisBlood and lymphatic system disorders2/42/3
Protein total decreasedInvestigations0/42/3
HypoalbuminemiaMetabolism and nutrition disorders1/42/3
HypocalcemiaMetabolism and nutrition disorders0/42/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Trilaciclib + DocetaxelPlacebo + DocetaxelTotal
<=18 years000
Between 18 and 65 years325
>=65 years112
Age, Continuous
Age, Continuous(years)Trilaciclib + DocetaxelPlacebo + DocetaxelTotal
Mean58.3 ± 11.4762.7 ± 2.5260.1 ± 8.57
Sex: Female, Male
Sex: Female, Male(Participants)Trilaciclib + DocetaxelPlacebo + DocetaxelTotal
Female213
Male224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Trilaciclib + DocetaxelPlacebo + DocetaxelTotal
Hispanic or Latino112
Not Hispanic or Latino325
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trilaciclib + DocetaxelPlacebo + DocetaxelTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American213
White224
More than one race000
Unknown or Not Reported000
ECOG Score
ECOG Score(Participants)Trilaciclib + DocetaxelPlacebo + DocetaxelTotal
0112
1224
2101
Stage at Diagnosis
Stage at Diagnosis(Participants)Trilaciclib + DocetaxelPlacebo + DocetaxelTotal
IV437
Unknown000
Histopathologic Type
Histopathologic Type(Participants)Trilaciclib + DocetaxelPlacebo + DocetaxelTotal
Adenocarcinoma325
Squamous Cell Carcinoma112
08

Study locations

12 sites
  • Ironwood Cancer & Research Centers
    Phoenix, Arizona 85028, United States
  • Valkyrie Clinical Trials
    Los Angeles, California 90067, United States
  • Desert Hematology Oncology Medical Group, Inc
    Rancho Mirage, California 92270, United States
  • Innovative Clinical Research Institute - Oncology
    Whittier, California 90602, United States
  • Mid-Florida Hematology Oncology
    Orange City, Florida 32763, United States
  • Indiana University Health Goshen Cancer Center
    Goshen, Indiana 46526, United States
  • St. Louis Cancer Care, LLP
    Bridgeton, Missouri 63044, United States
  • Summit Medical Group
    Florham Park, New Jersey 07932, United States
  • Regional Cancer Car Associates, LLC
    Little Silver, New Jersey 07739, United States
  • Gettysburg Cancer Center
    Gettysburg, Pennsylvania 17325, United States
  • University of Tennessee Medical Center
    Knoxville, Tennessee 37920, United States
  • Millennium Oncology
    Houston, Texas 77090, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Feb 2022, 9 months.

Results were first posted in Apr 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2021
First posted
Apr 28, 2021
StartActual
Apr 30, 2021
Primary completionActual
Feb 2, 2022
CompletionActual
Feb 2, 2022
Results first posted
Apr 14, 2023
Last update
Apr 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04863248
Responsible party
Sponsor
First posted
Apr 28, 2021
Start date
Apr 30, 2021
Primary completion
Feb 2, 2022
Completion
Feb 2, 2022
Results posted
Apr 14, 2023
Last update
Apr 14, 2023

Study contacts

Clinical Contact
study director · G1 Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trilaciclib

Start the discussion